Sustained complete response to cytotoxic therapy and the PARP inhibitor veliparib in metastatic castration-resistant prostate cancer - A case report

Frontiers in Oncology

Volumn 5, Issue JUL, 2015, Pages

  Van der Weele, David J ^a   Paner, Gladell P ^a   Fleming, Gini F ^a   Szmulewitz, Russell Z ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

BRCA2; Complete response; ERG; PARP inhibitor; Prostate cancer; TP53; Veliparib

Indexed keywords

BRCA2 PROTEIN; CARBOPLATIN; GEMCITABINE; PROTEIN P53; TRANSCRIPTION FACTOR ERG; VELIPARIB;

AGED; ARTICLE; CANCER CHEMOTHERAPY; CASE REPORT; CASTRATION RESISTANT PROSTATE CANCER; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MOLECULAR DIAGNOSIS; MULTIPLE CYCLE TREATMENT; PROTEIN EXPRESSION; TREATMENT OUTCOME; VERY ELDERLY;

EID: 84940105220     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2015.00169     Document Type: Article

References (21)

1. Huggins C, Hodges CV. Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res (1941) 1:293-7.
2. Brenner JC, Ateeq B, Li Y, Yocum AK, Cao Q, Asangani IA, et al. Mechanistic rationale for inhibition of poly(ADP-ribose) polymerase in ETS gene fusion-positive prostate cancer. Cancer Cell (2011) 19:664-78. doi:10.1016/j.ccr.2011.04.010.
3. Beltran H, Rickman DS, Park K, Chae SS, Sboner A, MacDonald TY, et al. Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets. Cancer Discov (2011) 1:487-95. doi:10.1158/2159-8290.CD-11-0130.
4. Tryggvadóttir L, Vidarsdóttir L, Thorgeirsson T, Jonasson JG, Olafsdóttir EJ, Olafsdóttir GH, et al. Prostate cancer progression and survival in BRCA2 mutation carriers. J Natl Cancer Inst (2007) 99:929-35. doi:10.1093/jnci/djm005.
5. Narod SA, Neuhausen S, Vichodez G, Armel S, Lynch HT, Ghadirian P, et al. Rapid progression of prostate cancer in men with a BRCA2 mutation. Br J Cancer (2008) 99:371-4. doi:10.1038/sj.bjc.6604453.
6. Castro E, Goh C, Olmos D, Saunders E, Leongamornlert D, Tymrakiewicz M, et al. Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer. J Clin Oncol (2013) 31:1748-57. doi:10.1200/JCO.2012.43.1882.
7. Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med (2009) 361:123-34. doi:10.1056/NEJMoa0900212.
8. Sandhu SK, Omlin A, Hylands L, Miranda S, Barber LJ, Riisnaes R, et al. Poly (ADP-ribose) polymerase (PARP) inhibitors for the treatment of advanced germline BRCA2 mutant prostate cancer. Ann Oncol (2013) 24:1416-8. doi:10.1093/annonc/mdt074.
9. Kaufman B, Shapira-Frommer R, Schmutzler RK, Audeh MW, Friedlander M, Balmaña J, et al. Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. J Clin Oncol (2014) 33(3):244-50. doi:10.1200/JCO.2014.56.2728.
10. Wu M, Wang X, McGregor N, Pienta KJ, Zhang J. Dynamic regulation of Rad51 by E2F1 and p53 in prostate cancer cells upon drug-induced DNA damage under hypoxia. Mol Pharmacol (2014) 85:866-76. doi:10.1124/mol.113.090688.
11. Mateo J, Hall E, Sandhu S, Omlin AG, Miranda S, Carreira S, et al. Lba20antitumour activity of the Parp inhibitor olaparib in unselected sporadic castration-resistant prostate cancer (crpc) in the Toparp trial. Ann Oncol (2014) 25(Supp 5):v1-41. doi:10.1093/annonc/mdu438.20.
12. Udager AM, Shi Y, Tomlins SA, Alva A, Siddiqui J, Cao X, et al. Frequent discordance between ERG gene rearrangement and ERG protein expression in a rapid autopsy cohort of patients with lethal, metastatic, castration-resistant prostate cancer. Prostate (2014) 74(12):1199-208. doi:10.1002/pros.22836.
13. Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun X-W, et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science (2005) 310:644-8. doi:10.1126/science.1117679.
14. Rubin MA, Maher CA, Chinnaiyan AM. Common gene rearrangements in prostate cancer. J Clin Oncol (2011) 29:3659-68. doi:10.1200/JCO.2011.35.1916.
15. Robinson D, Van Allen EM, Wu Y-M, Schultz N, Lonigro RJ, Mosquera J-M, et al. Integrative clinical genomics of advanced prostate cancer. Cell (2015) 161:1215-28. doi:10.1016/j.cell.2015.05.001.
16. Grasso CS, Wu Y-M, Robinson DR, Cao X, Dhanasekaran SM, Khan AP, et al. The mutational landscape of lethal castration-resistant prostate cancer. Nature (2012) 487:239-43. doi:10.1038/nature11125.
17. Donawho CK, Luo Y, Luo Y, Penning TD, Bauch JL, Bouska JJ, et al. ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models. Clin Cancer Res (2007) 13:2728-37. doi:10.1158/1078-0432.CCR-06-3039.
18. Wu W, Kong Z, Duan X, Zhu H, Li S, Zeng S, et al. Inhibition of PARP1 by small interfering RNA enhances docetaxel activity against human prostate cancer PC3 cells. Biochem Biophys Res Commun (2013) 442:127-32. doi:10.1016/j.bbrc.2013.11.027.
19. Cheng H, Zhang Z, Borczuk A, Powell CA, Balajee AS, Lieberman HB, et al. PARP inhibition selectively increases sensitivity to cisplatin in ERCC1-low non-small cell lung cancer cells. Carcinogenesis (2013) 34:739-49. doi:10.1093/carcin/bgs393.
20. Shelton JW, Waxweiler TV, Landry J, Gao H, Xu Y, Wang L, et al. In vitro and in vivo enhancement of chemoradiation using the oral PARP inhibitor ABT-888 in colorectal cancer cells. Int J Radiat Oncol Biol Phys (2013) 86:469-76. doi:10.1016/j.ijrobp.2013.02.015.
21. Owonikoko TK, Zhang G, Deng X, Rossi MR, Switchenko JM, Doho GH, et al. Poly (ADP) ribose polymerase enzyme inhibitor, veliparib, potentiates chemotherapy and radiation in vitro and in vivo in small cell lung cancer. Cancer Med (2014) 3(6):1579-94. doi:10.1002/cam4.317.